Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Benutzer: Gast

Titel:: Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
Dokumenttyp:: Zeitschriftenaufsatz
Autor(en):: Guttman-Yassky, Emma; Brunner, Patrick M.; Neumann, Avidan U.; Khattri, Saakshi; Pavel, Ana B.; Malik, Kunal; Singer, Giselle K.; Baum, Danielle; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Rose, Sharon; Jim On, Shelbi; Li, Xuan; Fuentes-Duculan, Judilyn; Estrada, Yeriel; Garcet, Sandra; Traidl-Hoffmann, Claudia; Krueger, James G.; Lebwohl, Mark G.
Zeitschriftentitel:: Journal of the American Academy of Dermatology
Jahr:: 2018
Band / Volume:: 78
Heft / Issue:: 5
Seitenangaben Beitrag:: 872-881.e6
Volltext / DOI:: doi:10.1016/j.jaad.2018.01.016
Verlag / Institution:: Elsevier BV
E-ISSN:: 0190-9622
Publikationsdatum:: 01.05.2018
BibTeX

Vorkommen: